Related Experiment Video

Updated: Mar 17, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

613

Targeting mTOR signaling by polyphenols: A new therapeutic target for ageing

Hamidreza Pazoki-Toroudi1, Hamed Amani1, Marjan Ajami2

  • 1Physiology Research Center and Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Ageing Research Reviews
|July 26, 2016
PubMed

Insights

Polyphenolic compounds show promise in slowing aging by targeting the mechanistic target of rapamycin (mTOR) pathway. This research explores how these compounds can potentially extend health span and promote longevity.

Area of Science:

  • Gerontology and molecular biology
  • Cellular senescence and aging pathways
  • Pharmacology of natural compounds

Background:

  • Current aging research focuses on extending health span, not just lifespan.
  • Cellular senescence plays a key role in age-dependent degeneration.
  • Polyphenols are natural compounds with potential therapeutic applications.

Purpose of the Study:

  • To investigate the mechanisms by which polyphenols delay aging.
  • To explore the role of polyphenols in targeting mTOR signaling pathways.
  • To discuss the implications of polyphenols for health span extension and longevity.

Main Methods:

  • Review of molecular and cellular pathways involved in aging.
  • Analysis of polyphenol mechanisms of action, particularly mTOR inhibition.
  • Discussion of research on polyphenols and age-related degeneration.

Main Results:

  • Polyphenols can delay the molecular pathogenesis of aging.
  • Inhibition of mTOR signaling pathways by polyphenols is a key mechanism.
  • Polyphenols offer a novel therapeutic strategy for age-related diseases.

Conclusions:

  • Polyphenols represent a promising therapeutic strategy for promoting healthy aging.
  • Targeting mTOR pathways with polyphenols can slow age-dependent degeneration.
  • Further research into polyphenols could revolutionize longevity and health span.
Keywords:
AgeingFlavonoidPolyphenolmTOR

More Related Videos

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

20.0K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
300
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.4K
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.2K